We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Loss of Smell Loss Can Predict Increased Mortality Risk

By HospiMedica International staff writers
Posted on 07 Apr 2017
A new study suggests that poor odor identification and poor self-reported olfactory function are associated with greater likelihood of future mortality, irrespective of dementia status.

Researchers at Umeå University, Stockholm University, and other institutions conducted a prospective study involving 1,774 adult participants (40-90 years of age) without dementia at baseline to determine whether dementia could explain the known association between poor olfactory performance and mortality risk. More...
The researchers gauged olfactory performance via the Scandinavian odor-identification test (SOIT) and self-reported olfactory function; noted social, cognitive, and medical risk factors at baseline; and followed incident dementia during the following decade.

The results revealed that during the study period, 411 of the participants (23%) died. After controlling for demographic, health-related, and cognitive confounders, each additional correctly identified odor lowered the risk of mortality by 8%. Individuals with chance level results on the SOIT tests (indicating complete olfactory loss) were at a 19% higher risk of death than individuals with normal smell function. The association between SOIT score and mortality was retained after controlling for dementia conversion before death. The study was published on March 22, 2017, in Journal of the American Geriatrics Society.

“The results contribute to the growing evidence that olfactory assessments might provide insights on the aging brain,” said senior author Professor Jonas Olofsson, PhD, of the psychology department at Stockholm University. “Our results were not explained by dementia, which was previously linked to smell loss. Instead, mortality risk was uniquely predicted by smell loss. In our future research, we will try to pinpoint the biological processes that can explain this phenomenon.”

Autopsy studies have linked olfactory loss (anosmia) with the plaques and tangles in the olfactory bulb, entorhinal cortex, and the cornu ammonis regions of the hippocampus. Reduced levels of choline acetyl transferase and dopamine in the olfactory tubercle and other brain regions may also play a role, as well as decreased norepinephrine due to neurodegeneration in the olfactory bulb. Anosmia has been previously linked with cognitive decline, mild cognitive impairment (MCI), and Alzheimer's disease (AD).


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.